<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110871">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783665</url>
  </required_header>
  <id_info>
    <org_study_id>13332</org_study_id>
    <nct_id>NCT01783665</nct_id>
  </id_info>
  <brief_title>The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis</brief_title>
  <official_title>The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catherine Siengsukon, PT, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In addition to the typical motor and sensory impairments, individuals with multiple
      sclerosis (MS) often experience cognitive dysfunction and sleep disturbances. Cognitive
      impairment occurs in 40 % - 70% of patients with MS. In addition, sleep problems in
      individuals with MS are very common, and approximately 50% of patients with MS have a
      diagnosable sleep disorder. The research believes that aerobic exercise improve cognitive
      function and improve sleep quality.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Cognitive Function</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Quality</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Aerobic Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3x/week supervised moderate intensity aerobic exercise on recumbent stepper</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Home exercise program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>aerobic exercise</intervention_name>
    <arm_group_label>Aerobic Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>home exercise program</intervention_name>
    <arm_group_label>Home exercise program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of relapsing remitting or secondary progressive MS

          -  score 3-7 on the EDSS

          -  score &lt; 55 on the Symbol Digit Modalities Test

          -  score &gt; 5 on the Pittsburgh Sleep Quality Index

        Exclusion Criteria:

          -  history of alcohol/drug abuse or nervous system disorder other than MS

          -  severe physical, neurological, or sensory impairments that would interfere
             significantly with testing

          -  developmental history of learning disability or attention-deficit/hyperactivity
             disorder

          -  relapse and/or corticosteroid use within four weeks of assessment

          -  unable to give consent

          -  uncorrected vision loss that would interfere significantly with testing

          -  score less than 24 on MMSE

          -  Acute ischemic cardiovascular event or coronary artery bypass surgery less than 3
             months ago

          -  Either unable to physically perform the exercise test using the recumbent stepper or
             demonstrate absolute indications for terminating exercise that follows the American
             College of Sports Medicine's (ACSM) guidelines

          -  Uncontrolled blood pressure with medication (BP &gt; 190/110mmHg)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Siengsukon, PT, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Siengsukon, PT, PhD</last_name>
    <phone>913-588-6913</phone>
    <email>csiengsukon@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Siengsukon, PT, PhD</last_name>
      <phone>913-588-6913</phone>
      <email>csiengsukon@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Catherine Siengsukon, PT, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
